NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

PolyPid logo
$6.15 -0.11 (-1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$6.18 +0.03 (+0.42%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About PolyPid Stock (NASDAQ:PYPD)

Advanced

Key Stats

Today's Range
$6.03
▼
$6.25
50-Day Range
$4.72
▼
$6.60
52-Week Range
$3.50
▼
$7.15
Volume
211,750 shs
Average Volume
168,040 shs
Market Capitalization
$117.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67
Consensus Rating
Moderate Buy

Company Overview

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered.

The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections. PolyPid has also explored its delivery platform for other medicines and applications.

PolyPid is headquartered in Israel and focuses on advancing its drug-delivery technology and product candidates through clinical development. Its products remain investigational and are not established as approved treatments.

AI Generated. May Contain Errors.

PolyPid Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

PYPD MarketRank™: 
3.218307060535 of 5 stars

PolyPid scored higher than 64% of companies evaluated by MarketBeat, and ranked 311th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PolyPid has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    PolyPid has a consensus price target of $11.67, representing about 89.7% upside from its current price of $6.15.

  • Amount of Analyst Coverage

    PolyPid has only been the subject of 3 research reports in the past 90 days.

  • Read more about PolyPid's stock forecast and price target.
  • Earnings Growth

    Earnings for PolyPid are expected to grow in the coming year, from ($0.92) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PolyPid is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PolyPid is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PolyPid has a P/B Ratio of 8.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.11% of the float of PolyPid has been sold short.
  • Short Interest Ratio / Days to Cover

    PolyPid has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PolyPid has recently increased by 98.34%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PolyPid does not currently pay a dividend.

  • Dividend Growth

    PolyPid does not have a long track record of dividend growth.

  • News Sentiment

    PolyPid has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for PolyPid this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for PYPD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added PolyPid to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PolyPid insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    26.47% of the stock of PolyPid is held by institutions.

  • Read more about PolyPid's insider trading history.
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PYPD Stock News Headlines

HC Wainwright Issues Positive Estimate for PolyPid Earnings
FY2029 Earnings Forecast for PolyPid Issued By HC Wainwright
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
PolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC Wainwright
PolyPid (NASDAQ:PYPD) Rating Lowered to Hold at Wall Street Zen
PolyPid Earnings Call Highlights D-PLEX100 Launch Path
PolyPid (PYPD) Q3 2026 Earnings Call Transcript
See More Headlines

PYPD Stock Analysis - Frequently Asked Questions

PolyPid's stock was trading at $4.34 at the beginning of 2026. Since then, PYPD shares have increased by 41.7% and is now trading at $6.15.

PolyPid Ltd. (NASDAQ:PYPD) posted its earnings results on Wednesday, November, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by $1.15. The company had revenue of $30 million for the quarter, compared to analyst estimates of $30 million.
Read the conference call transcript
.

PolyPid shares reverse split on Thursday, September 21st 2023.The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

PolyPid (PYPD) raised $60 million in an initial public offering on Friday, June 26th 2020. The company issued 3,750,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Top institutional shareholders of PolyPid include AIGH Capital Management LLC (6.53%), Marshall Wace LLP (1.05%), B. Riley Wealth Advisors Inc. (0.11%) and HighTower Advisors LLC (0.07%).

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), Intel (INTC), Walmart (WMT), Energy Transfer (ET), Salesforce (CRM), Johnson & Johnson (JNJ) and Micron Technology (MU).

Company Calendar

Last Earnings
11/11/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PYPD
CIK
1611842
Fax
N/A
Employees
72
Year Founded
2008

Price Target and Rating

High Price Target
$13.00
Low Price Target
$10.00
Potential Upside/Downside
+89.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.17 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-355.64%
Return on Assets
-157.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.35
Quick Ratio
1.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.69 per share
Price / Book
8.91

Miscellaneous

Outstanding Shares
19,083,000
Free Float
14,369,000
Market Cap
$117.36 million
Optionable
Optionable
Beta
1.43

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:PYPD) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners